About TAT 12
The 12th International Symposium on Targeted Alpha Therapy (TAT 12) will provide information on the newest developments in preclinical studies, clinical experiences, dosimetry and instrumentation, quality assurance, regulatory, targeting, radiochemistry, and nuclide production and supply. Participate in the latest discussions, scientific exchange and in focused networking with industry leaders from around the world.
TAT 12 will be held in Cape Town, South Africa from 27 February – 2 March 2023 at the Cape Town International Convention Centre 2 (CTICC 2).
TAT 12 continues a successful series of international symposia on this topic initiated by the Joint Research Centre of the European Commission, including meetings in Karlsruhe (1997, 2000), Heidelberg (2002), Düsseldorf (2004), Aachen (2007), Toronto (2009), Berlin (2011), Oak Ridge (2013), Warsaw (2015), Kanazawa (2017) and Ottawa (2019).
What you can expect to see
Keynote speakers from industry and academic leaders
Exhibits from leading industry members
TAT 12 Host
The University of Pretoria (UP)
The University of Pretoria is one of Africa’s top universities and the largest contact university in South Africa. The University produces socially impactful research to find solutions for the world’s most pressing issues and has a high quality of teaching and learning in the classroom, online, or in communities.
There is support in place for students to graduate on time as well-rounded, responsible citizens fully prepared for the world beyond university.
Joint Research Centre (JRC)
The Joint Research Centre serves as the European Commission’s science and knowledge service, providing scientific evidence throughout the whole policy cycle.
Starting in the early 1990’s, the JRC has developed the concept of Targeted Alpha Therapy from bench to bedside for over 30 years. Several applications of radiopharmaceuticals labelled with the alpha emitters Actinium-225 and Bismuth-213 were pioneered by JRC and its clinical partners, including first-in-human studies of alpha radiopharmaceuticals for therapy of leukemia, Non-Hodgkins Lymphoma, melanoma, brain tumors, neuroendocrine tumors and prostate cancer.
To foster scientific exchange and networking in the field, JRC has initiated this series of international symposia on targeted alpha therapy with a 1st meeting in Karlsruhe, Germany, in 1997. Following many successful meetings in Europe, North America and Asia with continuously growing attendance, TAT’12 will be the first symposium on the African continent, highlighting the close and fruitful collaboration of JRC and University of Pretoria in the development of targeted alpha therapy.
South African Society of Nuclear Medicine (SASNM)
The South African Society of Nuclear Medicine is a voluntary association governed by its constitution and bylaws.
SASNM was established in 1974 to provide a forum for collaboration between Physicians, Scientists, Radiographers and other professional persons with a common interest in the field of nuclear medicine.
Members promote the practice and development of nuclear medicine through the accumulation and dissemination of scientific and technical information. Membership is open to all persons who have an interest in the production and promotion, and diagnostic and therapeutic, use of radionuclides.
Control of the affairs of the Society is vested in a Council and Executive Committee whose members hold office for a 2-year term until their successors are elected at the following biennial SASNM meeting.
European Association of Nuclear Medicine (EANM)
The European Association of Nuclear Medicine is the largest organisation dedicated to nuclear medicine in Europe. In this role, it has become the umbrella organisation that represents the whole sector towards the European Institutions and other international institutions.
The International Atomic Energy Agency (IAEA)
The International Atomic Energy Agency is the world’s central intergovernmental forum for scientific and technical co-operation in the nuclear field. It works for the safe, secure and peaceful uses of nuclear science and technology, contributing to international peace and security and the United Nations’ Sustainable Development Goals.
World Association of Radiopharmaceutical and Molecular Therapy (WARMTH)
The World Association of Radiopharmaceutical and Molecular Therapy extends its activities throughout the world. WARMTH is the only worldwide organization founded to promote the use of radionuclide molecular therapy, and of the relatively novel paradigm of ‘Theragnostics’.
TAT 12 Co-chairs
Mike Sathekge – University of Pretoria, South Africa
Alfred Morgenstern – European Commission, Joint Research Centre, Karlsruhe, Germany
Mariza Vorster – University of KwaZulu-Natal, South Africa
Frank Bruchertseifer – European Commission, Joint Research Centre, Karlsruhe, Germany
Kgomotso Mokoala – University of Pretoria, South Africa
Stuart More – University of Cape Town, South Africa
Facial Azaiez – iThemba Labs, South Africa
Amanda Mdlophane – NuMeRI, South Africa
JanRijn Zeevaart – NECSA, South Africa
Otto Knoesen – European Commission, NTP, South Africa
Kohshin Washiyama – Fukushima Medical University, Japan
Ilhan Lim – Korea Institute of Radiological & Medical Sciences, South Korea
Chandrasekhar Bal – All India Institute of Medical Sciences, India
Louise Emmett – St Vincent’s Hospital, Australia
United States of America /Canada
Sandra Davern – Oak Ridge National Laboratory, United States of America
Stavroula Sofou – Johns Hopkins University, United States of America
Valery Radchenko – TRIUMF, Canada
Scott Wilbur – University of Washington, United States of America
Jeremie Calais – UCLA, United States of America
Lionel Zuckier – Montefiore Medical Center, United States of America
Elba Etchehebere – University of Campinas, Brazil, South America
Clemens Kratochwil – University Hospital Heidelberg, Germany
Christof Seidl – Technical University Munich, Germany
Jolanta Kunikowska – Medical University Warsaw, Poland
Thierry Stora – CERN, Switzerland
Jan Kozempel – Prague Technical University, Czech Republic
Joelle Gaschet – INSERM, France
Jean-Pierre Pouget – INSERM, France
Richard Baum – ICPO – Wiesbaden, Germany
Ora Israel – Rambam Health Care Campus, Israel
Francesco Giammarile – IAEA, France
Irene Virgolini – Medical University of Innsbruck, Austria
Ken Herrmann – University Hospital Essen, Germany